165 related articles for article (PubMed ID: 25443143)
1. Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005.
Hollenbeck BK
Urol Oncol; 2014 Oct; 32(7):1089. PubMed ID: 25443143
[TBL] [Abstract][Full Text] [Related]
2. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
[TBL] [Abstract][Full Text] [Related]
3. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Arends TJ; van der Heijden AG; Witjes JA
J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
5. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer.
Cookson MS; Chang SS; Oefelein MG; Gallagher JR; Schwartz B; Heap K
J Urol; 2012 May; 187(5):1571-6. PubMed ID: 22425105
[TBL] [Abstract][Full Text] [Related]
6. Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
Serretta V
J Urol; 2011 Oct; 186(4):1557. PubMed ID: 21855916
[No Abstract] [Full Text] [Related]
7. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
8. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
[TBL] [Abstract][Full Text] [Related]
9. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Lee HW; Lee HH; Park EY; Park WS; Kim SH; Joung JY; Chung J; Seo HK
J Urol; 2023 Jan; 209(1):131-139. PubMed ID: 36250938
[TBL] [Abstract][Full Text] [Related]
10. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
11. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
12. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
13. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
[TBL] [Abstract][Full Text] [Related]
14. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
Madeb R; Golijanin D; Noyes K; Fisher S; Stephenson JJ; Long SR; Knopf J; Lyman GH; Messing EM
Cancer; 2009 Jun; 115(12):2660-70. PubMed ID: 19455607
[TBL] [Abstract][Full Text] [Related]
15. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
[TBL] [Abstract][Full Text] [Related]
16. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
Richards KA; Smith ND; Steinberg GD
J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
[TBL] [Abstract][Full Text] [Related]
18. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer.
Barocas DA; Liu A; Burks FN; Suh RS; Schuster TG; Bradford T; Moylan DA; Knapp PM; Murtagh DS; Morris D; Dunn RL; Montie JE; Miller DC
J Urol; 2013 Dec; 190(6):2011-6. PubMed ID: 23792129
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer in Spain 2011: population based study.
Miñana B; Cózar JM; Palou J; Unda Urzaiz M; Medina-Lopez RA; Subirá Ríos J; de la Rosa-Kehrmann F; Chantada-Abal V; Lozano F; Ribal MJ; Rodríguez Fernández E; Castiñeiras Fernández J; Concepción Masip T; Requena-Tapia MJ; Moreno-Sierra J; Hevia M; Gómez Rodríguez A; Martínez-Ballesteros C; Ramos M; Amón Sesmero JH; Pizá Reus P; Bohorquez Barrientos A; Rioja Sanz C; Gomez-Pascual JA; Hidalgo Zabala E; Parra Escobar JL; Serrano O
J Urol; 2014 Feb; 191(2):323-8. PubMed ID: 23994371
[TBL] [Abstract][Full Text] [Related]
20. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
